Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AstraZeneca PLC - American Depositary Shares (NY:AZN)

189.90 -2.60 (-1.35%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 Next >
News headline image
The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis
In the high-stakes theater of corporate earnings calls, a "beat" on the bottom line used to be a guaranteed ticket to a stock price rally. However, as we move through the first quarter of 2026, a new... 
Via MarketMinute
Topics Artificial Intelligence Earnings Regulatory Compliance
News headline image
The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026
The opening months of 2026 have revealed a startling paradox in the global financial landscape: while the sheer number of corporate marriages is dwindling, the price tags on the few remaining... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering... 
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026
As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
Compugen (CGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
Via MarketBeat
Topics ETFs
News headline image
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
On February 2, 2026, AstraZeneca PLC (NYSE: AZN) officially rang the opening bell at the New York Stock Exchange, marking the completion of its high-profile transition from the Nasdaq. The move signals... 
Via MarketMinute
Topics ETFs
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
From AstraZeneca
Via Business Wire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
From AstraZeneca
Via Business Wire
News headline image
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
Via MarketBeat
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges
As of February 11, 2026, the corporate landscape is undergoing its most significant transformation in half a decade. After two years of high interest rates and regulatory gridlock that chilled the... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026
Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British... 
Via Finterra
Topics Artificial Intelligence Economy Fraud
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
AstraZeneca results: FY and Q4 2025
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade... 
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
OAK Family Advisors Sells $4 Million of NICE Stock ↗
This software firm delivers AI-driven cloud platforms for enterprise customer engagement and compliance across global markets. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.